A Study to Test if TEV-53275 is Effective in Relieving Asthma
- Study Title
- A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma
- Teva Identifier
- TV53275-AS-20033
- ClinicalTrials.gov Identifier
- NCT04847674
- Study Status
- Terminated
- Trial Condition(s)
- Asthma
- Interventions
- Drug: TEV-53275 Dose A | Drug: TEV-53275 Dose B | Drug: Placebo
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years and Older
- Trial Duration
- May 4, 2021 - April 28, 2022
- Phase
- Phase 2